Regional Performance Farxigas sales remain well-distributed across key markets: US: $1,752 million EU: $2,634 million Emerging Markets: $2,853 million Rest of the World: $478 million Global Adoption Farxigas cumulative lifetime sales since its launch in 2014 have now surpassed $20.9 billion a testament to its long-term commercial success
Visit us online
Its Active Component Is Semaglutide, and While Its Main Purpose Is to Help Regulate Blood Sugar Levels in People With Type 2 Diabetes, Ozempic Is Also Sometimes Prescribed Off-Label to Aid in Weight Loss
Behind the scenes, however, a new generation of GLP-1 medications is moving through clinical trials, with oral options, combination therapies and strong early results
Common signs of NAION include: Sudden, unilateral painless loss of vision Visual field defect (usually altitudinal) Blurred vision Dyschromatopsia (new onset impairment or loss of color vision) Relative afferent pupillary defect Optic disc swelling with or without hemorrhages A patient starting a GLP-1RAespecially if they have diabetes or age-related macular degeneration should have an in-person, comprehensive, dilated eye examination either within the 12 months prior to starting therapy or a baseline examination within one month of initiating therapy
But even with the high prices, GLP-1s are running off the shelves with shortages of Ozempic and Wegovy while Novo Nordisk announced it will cut back on supplying doses for new patients
